Rituximab, a chimeric mouse/human monoclonal antibody that binds to the CD20 antigen, is part of current treatment of many B-cell malignancies and several autoimmune diseases. Very few cases of rituximab administration during pregnancy have been described. We report here the case of rituximab administration during the first trimester of pregnancy in a woman with autoimmune hemolytic anemia. No significant effects were observed in B-cell counts or the immune status of the newborn.
Introduction
Rituximab is a genetically engineered mouse/human chimeric immunoglobulin (Ig)G1-k monoclonal antibody that contains murine light-and heavy-chain variable regions and human constant region sequences. It targets the CD20 antigen, a nonglycosylated phosphoprotein located on normal pre-B and Blymphocytes, but also on malignant cells. 1, 2 Although treatment with rituximab induces lymphopenia in most patients, typically lasting several months, a full recovery of B-lymphocytes in the peripheral blood is usually seen after therapy and does not appear to be associated with adverse consequences. 3, 4 Rituximab also depletes malignant and normal B-lymphocytes from lymph nodes and bone marrow, in animal models and clinical protocols. [5] [6] [7] Few data exist on rituximab administration during pregnancy. 8, 9 In one of the only two previous reports available at present, four initial rituximab doses combined with a nonalkylating chemotherapy were given from the 21st week of pregnancy to a 29-year-old female who had a diffuse large B-cell lymphoma. No unfavourable effects were observed in the healthy child, whose peripheral B-cell population was reported normal at 4 months of age. 8 In the other more extensive report, rituximab was administered unintentionally to a 37-year-old woman with nonHodgkin's lymphoma in the late first trimester of pregnancy. In this case also, no complications were observed with normal intrauterine growth of the fetus and without signs of abnormalities by ultrasound. After delivery of a healthy child, a transient slight lymphopenia and normal serum immunoglobulin levels were observed immediately after birth. Total lymphocyte count became normal by 16 days of life, and at 35 days post-partum, it was also reported as normal. 9 Given the negative findings in these other cases, we now report on a new case of rituximab administration in the first trimester of pregnancy during embryogenesis in a patient presenting with non-malignant disease.
Case presentation
A 41-year-old woman with a history of cardiac valvulopathy responsible for left ventricular failure (echocardiograph left ventricular ejection fraction 48%) was admitted in June 2004 with severe autoimmune hemolytic anemia (AIHA) diagnosed with the direct Coombs test positive to IgG and complement. She was initially treated with corticosteroids and concomitant packed red blood cell (RBC) transfusions, yielding a good response. After discharge, the patient's compliance with oral corticosteroid treatment was poor and she was admitted several weeks later with a similar clinical picture. She received a new course of intravenous corticosteroids (2 mg/kg body weight) with stabilization of hemolytic parameters. Again after discharge, drug compliance was poor and for the third time she was admitted for AIHA. This time, the response to corticosteroids and packed RBC transfusions was suboptimal, and after 2 weeks, the decision was made to begin the administration of a weekly course of rituximab (375 mg/m 2 ) (Mabthera s , Laboratories Roche, Basel, Switzerland). Four doses were administered with concomitant daily corticosteroids. Hemolytic parameters became stable and packed RBC transfusions were stopped.
The patient was discharged with a prescription for oral corticosteroids. She informed us of her pregnancy several weeks later and the French National Pharmacovigilance Commission was informed soon afterwards. By ultrasound dating, all the rituximab perfusions occurred during the first trimester, between 7 and 10 weeks of gestation. Corticosteroids were progressively decreased and stopped at the end of the second trimester. The fetal anatomy ultrasound in the 5th month of pregnancy was normal as well as the amniocentesis cytogenetic analysis that showed a 46 XX karyotype.
At 38 weeks of gestation, labor was induced with oxytocin in the setting of premature rupture of membranes at term and led to a vaginal delivery. The amniotic fluid was clear and the placenta macroscopic examination was normal. The newborn girl did well with Apgars of 10 at 1, 5 and 10 min, weight 3060 g, height 48.5 cm and head circumference of 34 cm. The physical examination was normal, except a mild bone depression at the sacrum-coccyx level. A possible diagnosis of spina bifida occulta was completely excluded. The spinal marrow ultrasound was normal without any fistula. A cerebral computed tomography scan was also normal.
Blood cell counts revealed a normal lymphocyte count at birth and moderate neutrophilia starting 24 h later, explained in part by a mild infection without microbiological or clinical documentation ( Table 1 ). The C-reactive protein value increased from 16 mg/l (N 0-5 mg/l) 12 h after delivery to 32 mg/l at 24 and 36 h postpartum. Clinical outcome was favorable in the setting of antibiotic treatment. C-reactive protein value was normal on the 5th day of life. Although the blood lymphocyte count was normal 24 h postdelivery, a short transient low count (1.4 Â 10 9 /l) was observed on the second day, showing a rapid recovery in the following days and persisting normal values several weeks later (Table 1) . On day 2 post-partum, serum IgG levels were normal (N 8.5-13.5 g/l) and undetectable IgA and IgM levels were also considered as normal (N: IgA 0-0.05 g/l; IgM 0-0.16 g/l; Table 1 10,11 Immunophenotyping of cord blood cells showed the presence of mature B cells as well as B precursors among the CD34 þ cell population, both also detected in the peripheral blood 3 and 55 days post-partum (Table 2 ). At 6 months of age, the child is doing well with normal growth and psychomotor development. No particular susceptibility to infections has been observed.
Discussion
Rituximab is usually well tolerated in patients with both malignant and non-malignant diseases, including children. 12 The safety of using rituximab during pregnancy is not known.
2 No long-term animal studies have been performed to determine its effects on fertility in males or females. Standard tests to investigate mutagenicity have not been carried out. However, owing to its character, it is unlikely that rituximab has any mutagenic potential. 2 The pharmacology and toxicology of rituximab was evaluated in preclinical studies in macaque cynomolgus, which established the preclinical basis for clinical trials with rituximab in humans. Recently, a toxicology study carried out in pregnant macaque cynomolgus females that received rituximab at different doses (20, 50 or 100 mg/kg) during the period of organogenesis (gestation days 20-50) did not show any embryotoxic or teratogenetic effect on offspring delivered at 100 gestational days on macroscopic and histological examination. The only pharmacological treatmentrelated effect observed was a B-cell depletion. 7 Very few reports exist concerning its administration during pregnancy in humans. 8, 9 Given rituximab's pharmacokinetic properties, 3, 4, 13 and as IgG is known to pass the placental barrier, its administration during pregnancy should consider the potential risk of B-cell depletion in the fetus and newborn. 2 In the two previous reports, both were in the setting of pregnant women with non-Hodgkin's lymphoma. In one of these cases, it was used in combination with a non-alkylating chemotherapy. 8 In the other case, the patient had received a previous cycle of rituximab several months earlier and also a cycle of 2-chlorodeoxy-adenosine (cladribine) years before. 9 In contrast, the pregnant woman we treated had no malignant B disease and had never received any chemotherapy. In our case, no significant adverse influence on the health status of the newborn can be concluded. Nevertheless, similar to one previous report, a transient and slight lymphopenia was observed. 9 One difference was that the lymphopenia was already present immediately post-partum in this prior report compared to our observation where it occurred between the second and third day post-partum (Table 1) . Although this low lymphocyte count was slight and particularly short lasting, we cannot fully exclude it as a potential rituximabrelated effect.
The mild infection observed during post-partum is likely not related to this transient lymphopenia that improved rapidly, because already on day 4 post-partum, the total lymphocyte count was normal again (Table 1) . This is different to the more longlasting lymphopenia observed in lymphoma patients treated with rituximab alone or associated to chemotherapy. [1] [2] [3] [4] Concerning the mild bone depression at the sacrum-coccyx level, not only was the diagnosis of spina bifida occulta definitively excluded but also no arguments in favor of any rituximab-related teratogenicity can be concluded. Moreover, like our patient most other patients do not experience significant changes in serum Ig levels. 3, 14 However, disturbances in the humoral immune response have been reported. 14 In this newborn, the low post-partum serum IgA and IgM levels (Table 1) , also observed in a similar report, 9 appear more related to the fact that usually these Igs are low or not detected after birth, in contrast to IgG that are mostly of maternal origin. 15 Moreover, IgM levels became normal 2 weeks postdelivery, implying perhaps a post-infection stimulation. 16 No significant adverse effect on B lymphopoiesis can be concluded because mature B cells and B-cell precursors were detected at birth as well as several days and weeks later (Table 2) . Moreover, because CD20 appears not to be expressed on primitive hematopoietic stem cells, normal re-emergence of mature B cells is expected. 17 We are unable to determine the impact rituximab had in the fetal B-cell compartment at a time when lymphopoiesis is Rituximab during first trimester of pregnancy M Ojeda-Uribe et al arising in fetal hematopoiesis. 2 However, even if a B-cell depletion occurred, we think that since the last dose of rituximab, enough time elapsed to allow a good recovery.
